List view / Grid view
3 December 2013 | By Novo Nordisk
Data presented at the World Diabetes Congress of the International Diabetes Federation show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia...
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...
3 December 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).
2 December 2013 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for ALPROLIX...
2 December 2013 | By Boehringer Ingelheim
The survey was developed in partnership with the International Diabetes Federation (IDF) and will include more than 10,000 people with T2D and more than 6,500 treating-physicians...
29 November 2013 | By Novartis
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria...
29 November 2013 | By Daiichi Sankyo Company,
Biopten is a highly pure, chemically synthesized form of natural tetrahydrobiopterin (hereafter, BH4) that occurs naturally in the human body...
28 November 2013 | By Novartis
Novartis scientists have discovered a new drug target for treating malaria...
28 November 2013 | By GlaxoSmithKline
GSK announced that the European Medicines Agency's Committee for Medicinal Products for Human Use is recommending marketing authorisation for a two-dose schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix™...
27 November 2013 | By Mettler Toledo
Mettler-Toledo announced an upcoming webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing" with special guest presenter Mr. Gregory Martin, President of Complectors Consulting LLC...
26 November 2013 | By kdm communications limited
Complementing the laboratory’s existing liquid displacement Freedom EVO platforms for DNA extraction, this new instrument will help to streamline the workflow and improve pipetting precision...
26 November 2013 | By Boehringer Ingelheim
The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...
25 November 2013 | By Cubist
“We are very pleased with these positive results, which represent a significant milestone for both ceftolozane/tazobactam and Cubist...”
25 November 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical…
25 November 2013 | By TEVA
Teva Pharmaceutical Industries Ltd. issued the following statement regarding an article published by The Marker...
